Zoledronic Acid Associated With Higher Risk for Atrial Fibrillation Than Denosumab

January 22, 2021

“Based on 16,235 pairs of zoledronic acid and denosumab initiators (for osteoporosis), we found a greater risk (HR 1.25, 95% CI 1.04-1.50) of atrial fibrillation with zoledronic acid vs denosumab: an absolute risk difference of 3.69 events per 1000 person-years,” said Seoyoung Kim, MD, ScD.

Bisphosphonates Show No Significant Benefit for Hip Fracture Risk after Five Years

January 19, 2021

Dr Joan Lo, MD, a research scientist with the Kaiser Permanente Northern California Division of Research, said: “We found that hip fracture risk in women did not differ if women stopped bisphosphonate use after five years or stayed on the medication for 10 years. Whether there is a benefit to staying on the drug for seven years needs to be further studied in randomized trials.”

Study Highlights Osteoporosis Risk in Gay Men

December 10, 2020

Non-heterosexual minority men have a greater risk of poor bone health than heterosexual men, and this risk appears to be independent of lifestyle and psychosocial factors, suggests a study published in the American Journal of Human Biology.

Readers Pick the Best of Rheumatology for 2020

December 04, 2020

Stories on COVID-19 were no doubt among our most read stories in 2020, but so too were stories on diet and rheumatic disease, rheumatoid arthritis treatment options, a new treatment for osteoarthritis and a story about selecting appropriate exercise regimens for rheumatic conditions. In this slideshow, we highlight the stories that resonated most with our readers in 2020.

Osteoporosis Not Just a Disease of Women

November 25, 2020

In this interview, Jeffrey Curtis, M.D., of the University of Alabama at Birmingham, addresses osteoporosis in men. It's more common than physicians may realize. "It is often misconstrued as a disease that mainly, if not only, effects Caucasian women, which is not the case,” he said.